icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir (BMS-650032, ASV)
 
 
  Reported by Jules Levin
AASLD 2012 Nov 9-12 Boston MA
 
Eley T,1 He B,1 Li J,1 Colston E,1 Child M,1 Bedford BR,1 Kandoussi H,1 Wind-Rotolo M,1
Pasquinelli C,1 DeMicco MP,2 Marbury TC,3 Bertz RJ1
1Bristol-Myers Squibb Research and Development, Princeton, NJ; 2Advanced Clinical Research Institute, Anaheim, CA; 3Orlando Clinical Research Center, Orlando, FL
 
AASLD: Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)
 
AASLD: BMS at AASLD - (11/18/13)

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif